Evidence map›Paper›PMID 41255311›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Hepatocyte-Derived Extracellular Vesicles Deliver miR-328-3p to Trigger PP2A-B56δ-Mediated p-NLRP3

Jia-Shen Wu, Xin-Yu Zhang, Xin-Yu Ma, Yue-Yue Wei, Lei-Lei Wang, Ze-Bang Du, Xiao-Gang Xia, Lin Che, Dong-Bei Guo, Han-Ying Zheng and 4 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jia-Shen WuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Xin-Yu ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Xin-Yu MaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Yue-Yue WeiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Lei-Lei WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Ze-Bang DuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Xiao-Gang XiaDepartment of Hepatobiliary Surgery, Cancer Research Center, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China.
Lin CheState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Dong-Bei GuoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Han-Ying ZhengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
You-Liang YaoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Wen-Gang LiDepartment of Hepatobiliary Surgery, Cancer Research Center, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361102, China.
Yu-Chun LinState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.
Zhong-Ning LinState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory,Xiang'an Hospital of Xiamen University, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Public Health, Xiamen University, Xiamen, 361102, China.ORCID https://orcid.org/0000-0003-1717-0500

Funding

Fujian Province Special Fund Project for Promoting High-Quality Development of Marine and Fishery Industries FJHYF-L-2025-04-008Fundamental Research Funds for the Central Universities 20720250004Industry-University-Research Cooperation Project of Fujian Science and Technology Plan 2022Y4009National Natural Science Foundation of China 82273667National Natural Science Foundation of China 82574139Scientific Research Foundation of State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory 2023XAKJ0101024XMU Undergraduate Innovation and Entrepreneurship Training Programs 202210384050XMU Undergraduate Innovation and Entrepreneurship Training Programs 2022X1157XMU Undergraduate Innovation and Entrepreneurship Training Programs 2023X804XMU Undergraduate Innovation and Entrepreneurship Training Programs S202110384388
6 · The paper itself

Abstract

Microcystin-LR (MC-LR) exacerbates metabolic dysfunction-associated steatotic liver disease (MASLD) by inducing histopathological damage and lipid metabolism disorders. Inducible hepatocyte-derived extracellular vesicles (iHD-EVs) released after xenobiotic exposure activate the macrophage NOD-like receptor protein 3 (NLRP3) inflammasome. Suppression of NLRP3 phosphorylation at serine 295 (p-NLRP3

Indexed as

Extracellular VesiclesHepatocytesMacrophagesMicrocystinsMicroRNAsNLR Family, Pyrin Domain-Containing 3 ProteinProtein Phosphatase 2AnimalsHumansInflammasomesMaleMarine ToxinsMiceMice, Inbred C57BLcyanoginosin LRInflammasomesMarine ToxinsMicrocystinsMicroRNAsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseProtein Phosphatase 2Extracellular vesicle miR‐328‐3pMC‐LR‐associated MASLDp‐NLRP3S295‐dependent metaflammationPP2A‐B56δSite‐specific monoclonal antibody

Identifiers

PMID41255311
PMCPMC12866802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.